Elevated tumor-associated antigen CA 19-9 in a patient with an enlarged pancreas: Does it always imply malignancy?

Southern Medical Journal

Volumn 90, Issue 1, 1997, Pages 89-90

  Tolliver, Beth A ^a,b   O'Brien, Barbara L ^a,b,c  

^a College of Medicine ^*

^b UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CEFTRIAXONE; CLINDAMYCIN; GENTAMICIN;

ADULT; ARTICLE; BILE DUCT DILATATION; BILIARY TRACT DRAINAGE; CASE REPORT; CHRONIC PANCREATITIS; CLINICAL FEATURE; COMMON BILE DUCT DISEASE; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LABORATORY TEST; MALE; MEDICAL RECORD; PANCREAS RESECTION; PHYSICAL EXAMINATION; SPHINCTEROTOMY;

EID: 0031028354     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007611-199701000-00023     Document Type: Article

References (14)

1. Koprowski H, Steplewski Z, Mitchell K, et al: Colorectal carcinoma antigens detected by hybridoma antibodies. Somat Cell Genet 1979; 5:957-972
2. Del Villano BC, Brennan S, Brock P, et al: Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem 1983; 29:549-552
3. Dietel M, Arps H, Klapdor R, et al: Antigen detection by the monoclonal antibodies CA 19-9 and CA 125 in normal and tumor tissue and patients' sera. J Cancer Res Clin Oncol 1986; 111:257-265
4. Ritts RE, Del Villano BC, Go VL, et al: Initial clinical evaluation of an immunoradiometric assay for CA 19-9 using the NCI serum bank. Int J Cancer 1984; 33:339-345
5. Andriulli A, Gindro T, Piantino P, et al: Prospective evaluation of the diagnostic efficacy of CA 19-9 assay as a marker for gastrointestinal cancers. Digestion 1986; 33:26-33
6. Malesci A, Tommansini MA, Bonato C, et al: Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis. Gastroenterology 1987; 92:60-67
7. Piantino P, Andriulli A, Gindro T, et al: CA 19-9 assay in differential diagnosis of pancreatic carcinoma from inflammatory pancreatic diseases. Am J Gastroenterol 1986; 81:436-439
8. Steinberg WM, Gelfand R, Anderson KK, et al: Comparison of the sensitivity and specificity of the CA 19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. Gastroenterology 1986; 90:343-349
9. Forsmark CE, Lambiase L, Vogel SB: Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA 19-9. Pancreas 1994; 9:731-734
10. Schmiegel W: Tumor markers in pancreatic cancer-current concepts. Hepatogastroenterology 1989; 36:446-449
11. Steinberg W: The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990; 85:350-355
12. Mauer KR, Lopatin RN, Hoffman WA, et al: Decrease in a markedly elevated CA 19-9 level after stenting of a benign pancreatic ductal stricture. Gastrointest Endosc 1995; 42:261-263
13. Albert MB, Steinberg WM, Henry JP: Elevated serum levels of tumor marker CA 19-9 in acute cholangitis. Dig Dis Sci 1988; 33:1223-1225
14. Ker CG, Chen JS, Lee KT, et al: Assessment of serum and bile levels of CA 19-9 and CA 125 in cholangitis and bile duct carcinoma. J Gastroenterol Hepatol 1991; 6:505-508